Finance

Lists
4016:TADAWUL
Middle East Pharmaceutical Industries Co
SAR 62.40
+1.13%
(+0.70) 1D
Oct 15, 3:15:27 PM GMT+3  ·   SAR
All symbols
SymbolPriceChange% Change
Generating top insights for 4016...
Open
SAR 61.80
High
SAR 62.50
Low
SAR 61.50
Mkt. cap
2.18B
Avg. vol.
50.58K
Volume
44.87K
Dividend
2.49%
Quarterly dividend
SAR 0.39
Ex-dividend date
Sep 2, 2026
P/E ratio
20.13
52-wk high
SAR 79.10
52-wk low
SAR 53.90
EPS
SAR 3.10
Shares outstanding
21.55M
No. of employees
731
Open
SAR 61.80
High
SAR 62.50
Low
SAR 61.50
Mkt. cap
2.18B
Avg. vol.
50.58K
Volume
44.87K
Dividend
2.49%
Quarterly dividend
SAR 0.39
Ex-dividend date
Sep 2, 2026
P/E ratio
20.13
52-wk high
SAR 79.10
52-wk low
SAR 53.90
EPS
SAR 3.10
Shares outstanding
21.55M
No. of employees
731
News stories
From web sources and news partners
About Middle East Pharmaceutical Industries Co
CEOMohamed Maher Al Ghannam
Employees731
Founded1998
HeadquartersRiyadh, Riyadh Province, Saudi Arabia
SectorPharmaceutical industry
Websiteavalonpharmaceutical.com
Previous reportsAll values in SAR
Loading Previous Earnings...
Revenue
Net income
All values in SAR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
107.95M
137.52M
130.13M
136.48M
Cost of goods sold
45.81M
47.32M
49.78M
51.36M
Cost of revenue
45.81M
47.32M
49.78M
51.36M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
50.78M
43.26M
48.09M
51.16M
Operating expense
51.48M
43.77M
50.05M
51.43M
Total operating expenses
97.29M
91.08M
99.83M
102.79M
Operating income
10.66M
46.43M
30.30M
33.70M
Other non operating income
-
-
-
-
EBT including unusual items
9.82M
45.93M
29.13M
30.82M
EBT excluding unusual items
9.82M
45.89M
29.13M
30.82M
Income tax expense
1.54M
1.41M
2.23M
2.01M
Effective tax rate
15.69%
3.07%
7.67%
6.54%
Other operating expenses
-147.78K
-109.44K
-54.06K
-268.26K
Net income
8.28M
44.52M
26.90M
28.80M
Net profit margin
7.67%
32.38%
20.67%
21.10%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-844.49K
-562.26K
-1.16M
-2.88M
Net interest expenses
-844.49K
-562.26K
-1.16M
-2.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
13.78M
49.70M
33.47M
37.11M
Gain or loss from assets sale
-40.87K
-55.44K
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps